BPC-157 + TB-500 – User Manual & Dosage Protocol Guide

BPC-157 + TB-500 is a research peptide combination studied in regenerative and soft-tissue repair models.

• BPC-157 (Body Protection Compound-157) is a synthetic peptide derived from a gastric protein fragment.
• TB-500 (Thymosin Beta-4 fragment) is a synthetic peptide modeled after the naturally occurring thymosin beta-4 protein.

The combination is investigated in musculoskeletal and recovery research environments.

Research Applications

• Soft tissue recovery models
• Tendon and ligament research
• Muscle repair investigations
• Angiogenesis studies
• Inflammatory response modulation research

Disclaimer: BPC-157 and TB-500 are for research and experimental use only in this context. They are not FDA-approved for therapeutic use.

Lyophilized Dual Vial Kit

Separate freeze-dried vials of BPC-157 and TB-500

Combined Lyophilized Blend

Single vial containing both peptides

Reconstituted Solution

Injectable research preparation after dilution

Concentration and ratio vary by supplier.

BPC-157 is studied for its potential to:

• Support angiogenesis in injury models
• Influence collagen synthesis pathways
• Modulate inflammatory signaling
• Support tendon-to-bone healing research

TB-500 is studied for its potential to:

• Promote actin regulation in cell migration models
• Support tissue remodeling research
• Influence angiogenic activity
• Enhance recovery signaling pathways

The combination is investigated for potential complementary activity in tissue repair models.

Effects are primarily observed in animal and preclinical studies.

There is no approved dosage outside regulated clinical use. The following reflects common research patterns only.

Subcutaneous (SC) Research Model

BPC-157

Typical range: 200–500 mcg

Frequency: Once daily

Notes: Often localized near research site

TB-500

Typical range: 2–5 mg

Frequency: 2–3 times weekly

Notes: Often systemic research model

Loading Phase (Some Research Models)

TB-500

Range: 4–10 mg weekly (divided doses)

Duration: 2–4 weeks

After loading, maintenance frequency is typically reduced.

Human equivalent dosing has not been formally established. Values above reflect investigational research ranges only.

Initiation Phase

Duration: 1–2 weeks

Purpose: Tolerance and early response observation

Active Study Phase

Duration: 4–8 weeks

Purpose: Tissue repair and functional evaluation

Extended Research Phase

Duration: Up to 12 weeks

Purpose: Long-term remodeling observation

Rest Period

Duration: 2–4 weeks

Purpose: Washout between cycles

Cycle design depends on injury model and research objective.

Supplies

• Sterile bacteriostatic water
• Sterile syringe
• Alcohol swabs

General Procedure

1. Clean vial stopper with alcohol.
2. Add bacteriostatic water to desired concentration.

• Example: 5 mg vial + 2 mL → 2.5 mg/mL

1. Swirl gently to dissolve (do not shake).
2. Refrigerate at 2–8°C after reconstitution.
3. Use within 2–4 weeks or per research protocol.

Avoid excessive agitation to preserve peptide structure.

Subcutaneous Injection Model

• Common sites: abdomen or near research-target tissue (in localized models)
• Clean site prior to administration
• Inject slowly
• Rotate injection sites

Sterile handling procedures must be followed at all times.

Lyophilized Powder

Storage: Cool, dry environment

Shelf life: Up to 12 months

Reconstituted Solution

Storage: Refrigerated (2–8°C)

Shelf life: 2–4 weeks

Protect From:

Heat, light, and contamination

Discard if the solution appears cloudy or discolored.

• Research use only
• Not approved for therapeutic application
• Human safety outside controlled research is not established
• Possible research observations may include:
• Injection-site irritation
• Temporary fatigue
• Mild headache
• Transient nausea

Long-term safety data in humans remains limited.

Maintain sterile technique at all times.

Keep out of reach of children.

Peptides: BPC-157 + TB-500
Category: Regenerative / Tissue Repair Research
Delivery Model: Subcutaneous research injection
Typical Investigational Range:

• BPC-157: 200–500 mcg daily
• TB-500: 2–5 mg 2–3x weekly
  Cycle: 4–8 week research models
  Storage: Refrigerated after reconstitution